Skip to content Skip to footer
Subscribe Now
Viewpoints_Justin Odegaard
VIEWPOINTS
PharmaShots Interview: Guardant Health’s Justin Odegaard Shares Insight on the US FDA’s Approval of Guardant360 CDx for Amgen’s Lumakras
In an interview with PharmaShots, Justin Odegaard, Vice President of Clinical Development at Guardant Health shares his views on the Guardant360 CDx approval as the first & only liquid biopsy companion diagnostic for Amgen's Lumakras (sotorasib) KRASG12C inhibitor for use in advanced NSCLC. Shots: Guardant Health received the US FDA's approval for Guardant360 CDx liquid biopsy for use in conjunction…
July 29, 20210Comments
Viewpoints_Dr. Krishnansu S. Tewari and Israel Lowy
VIEWPOINTS
PharmaShots Interview: Dr. Krishnansu S. Tewari and Israel Lowy Share Insight on P-III Data of Libtayo Presented at ESMO Virtual Plenary
In an interview with PharmaShots, Krishnansu S. Tewari, Professor and Director of the Division of Gynecologic Oncology at the University of California, and Israel Lowy, Senior Vice President, Translational and Clinical Sciences, Oncology at Regeneron share their views on the data of Libtayo in cervical cancer patients, presented at ESMO Virtual Plenary. Shots: Regeneron and Sanofi reported…
July 28, 20210Comments
Viewpoints_Dr. David Spetzler
VIEWPOINTS
PharmaShots Interview: Caris Life Sciences’ Dr. Spetzler Shares Insight on AI-Based MI FOLFOXai Predictor
In a recent interview with PharmaShots, Dr. Spetzler, President and Chief Scientific Officer of Caris Life Sciences shared his insights on FOLFOXai and its importance in patients with metastatic colorectal cancer. He also highlights the data supporting the use of FOLFOXai as a predictor of CT efficacy in patients with mCRC. Shots: The validation studies of MI…
July 27, 20210Comments
Viewpoints_Dr. Andrew Krivoshik
VIEWPOINTS
PharmaShots Interview: Astellas’ Dr. Andrew Krivoshik Shares Insights on P-II FAST Study of Zolbetuximab
In an interview with PharmaShots, Dr. Andrew Krivoshik, Senior Vice President and Oncology Therapeutic Area Head at Astellas, shared his views on the P-II FAST study result published in the journal Gastric Cancer and highlights the data published in Annals of Oncology. Shots: The data from P-II FAST study evaluating zolbetuximab + EOX in 1L patients with advanced gastric and…
July 26, 20210Comments
Viewpoints_Tony Ezell
VIEWPOINTS
PharmaShots Interview: BD’s Tony Ezell Shares Insights on the Collaboration with USATF to Provide COVID – 19 Testing for US Athletes
In an interview with PharmaShots, Tony Ezell, President, North America and Chief Marketing Officer, BD shares its agreement with the USA Track and Field team for COVID-19 testing for the Olympic Trials. Shots: BD's partnership with USATF is part of the company's commitment to helping get people back to their normal lives The BD Veritor…
July 21, 20210Comments
Thoughtspot_Senior Editor
THOUGHTSPOT
Ethno-Pharma- An Emerging Sector
The Healthcare sector in 2021 is evolving to a greater extent owing to the initiatives and advancements taking place to futureproof the healthcare facilities from uncertain, unwanted, and deadly events like Covid-19. These advancements are happening while keeping the patients at the center with more focus on preventive and immune health.  Now while talking about…
July 21, 20210Comments
Viewpoints_Dave Marek
VIEWPOINTS
PharmaShots Interview: Myovant’s Dave Marek Shares Insights on the US FDA’s Approval of Myfembree in Uterine Fibroids
In an interview with PharmaShots, Dave Marek. CEO of Myovant shares insights on the US FDA's approval of Myfembree (relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5mg) in Uterine Fibroids. Shots: The US FDA has approved Myovant & Pfizer's Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as the first once-daily treatment for the…
July 20, 20210Comments
Viewpoints_Mark Wildgust, Paolo Ghia & Paul Barr
VIEWPOINTS
PharmaShots Interview: Janssen’s Mark Wildgust along with Two Other Key Speakers Share Insights on Data Presented at ASCO 2021
In an interview with PharmaShots, Mark Wildgust, VP of Global Medical Affairs, Oncology at Janssen, Dr. Paolo Ghia, Division of Experimental Oncology at Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele and Paul Barr, Associate Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Institute at University of Rochester…
July 19, 20210Comments

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]